Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata by Pasmatzi, Efstathia et al.
UC Davis
Dermatology Online Journal
Title
Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata
Permalink
https://escholarship.org/uc/item/4cm7b5qs
Journal
Dermatology Online Journal, 26(2)
Authors
Pasmatzi, Efstathia
Badavanis, George
Kapranos, Nikiforos
et al.
Publication Date
2020
License
https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 26 Number 2| February 2020| 
26(2):14 
 
 
- 1 - 
Dermatology Online Journal  ||  Photo Vignette 
Erythema nodosum induced by oral isotretinoin in a patient 
with condylomata acuminata 
Efstathia Pasmatzi1, George Badavanis2, Nikiforos Kapranos3, Alexandra Monastirli1,2, Dionysios Tsambaos1,2 
Affiliations: 1Department of Dermatology, School of Medicine, University of Patras, Greece, 2Center for Dermatologic Diseases, 
Limassol, Cyprus, 3Laboratory for Molecular Histopathology, Athens, Greece 
Corresponding Author: Efstathia Pasmatzi, M.D., Associate Professor, Department of Dermatology, School of Medicine, University of 
Patras, P.O. Box 1413, 26504 Rio-Patras, Greece, Tel: 30-2610 270577, Fax: 30-2610 270235, Email: pasmatzi@otenet.gr, 
pasmatzi@med.upatras.gr 
 
 
 
 
Keywords: isotretinoin, erythema nodosum, condylomata 
acuminata 
 
Introduction 
Erythema nodosum (EN) is a form of septal 
panniculitis, which is considered to represent a 
delayed hypersensitivity reaction activated by 
infectious agents, drugs, granulomatous and 
autoimmune diseases, pregnancy and malignancies 
[1]. Erythema nodosum has a female predilection 
(ratio 5:1) and more frequently occurs between the 
second and the fourth decades of life. It is clinically 
characterized by the presence of red or violaceous, 
painful, non-ulcerating subcutaneous nodules, 
typically occurring in crops located on the extensor 
aspect of the lower limbs and rarely on the trunk or 
the upper extremities [1, 2]. Nodules are often 
accompanied by systemic signs and symptoms and 
usually resolve without scarring after two to eight 
weeks. 
Isotretinoin (13-cis-retinoic acid), is a representative 
of the first retinoid generation, which was originally 
approved in 1982 by the US Food and Drug 
Administration (FDA) for the oral treatment of 
severe, recalcitrant nodular acne that is 
unresponsive to conventional therapy. Since then, 
oral isotretinoin has revolutionized the treatment of 
acne and is still regarded as the drug of choice for 
severe forms of this disease [3, 4]. However, owing to 
its pleiotropic immunomodulatory, anti-neoplastic, 
and anti-inflammatory actions, isotretinoin has also 
been successfully used as an off-label therapy for 
various diseases including among others rosacea, 
skin neoplasms including cutaneous T-cell 
lymphomas, hidradenitis suppurativa, granuloma 
annulare, lupus erythematosus, lichen planus, and 
condylomata acuminata [5]. Isotretinoin’s most 
important side effects are teratogenesis, 
hyperlipidemia, hepatotoxicity, mucocutaneous 
dryness, photosensitivity, and neurologic adverse  
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Erythema nodosum (EN) is a form of septal 
panniculitis, which is believed to represent a delayed 
hypersensitivity reaction activated by infectious 
agents, drugs, granulomatous and autoimmune 
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only four reported cases of EN during oral isotretinoin 
therapy to our knowledge, all of them occurring in 
patients with severe acne. Since acne itself can 
trigger EN, the question as to whether there is indeed 
a causative relationship between isotretinoin and EN 
in the reported cases remains to be elucidated. We 
present herein a 20-year-old woman with multiple 
vulvar condylomata acuminata who developed EN 
two weeks after onset of oral isotretinoin therapy. To 
the best of our knowledge, this is the first report of EN 
occurring during isotretinoin treatment in a patient 
without acne and strongly indicates that the 
pathogenesis of EN can be directly related to the 
biological actions of isotretinoin. Erythema nodosum 
should be regarded as a rare side effect of oral 
isotretinoin therapy, regardless of the underlying 
disease. Physicians should be aware of this rare side 
effect. 
Volume 26 Number 2| February 2020| 
26(2):14 
 
 
- 2 - 
Dermatology Online Journal  ||  Photo Vignette 
reactions (headache, depression, disulfiram-like 
reactions, pseudotumor cerebri, dizziness, 
oculogyric crisis, and decreased hearing), [4]. 
In an attempt to improve the awareness among 
physicians of EN being a rare side effect of 
isotretinoin, we present herein the case of a 20-year-
old woman with multiple vulvar condylomata 
acuminata who presented with EN two weeks after 
onset of oral isotretinoin therapy.  
 
Case Synopsis 
A 20-year-old HIV-negative woman presented with a 
7-month-history of multiple condylomata acuminata 
on the vulva, which had relapsed three months after 
treatment with electrocauterization. She had no 
history or evidence of autoimmune or neoplastic 
disorders and systemic infections. Moreover, a 
meticulously taken medication history revealed the 
intake of no currently or recently prescribed drugs or 
over-the counter medications. In particular, the 
patient, being aware of the side effects and risks 
associated with oral contraceptives, had never used 
them, but chose other methods of contraception. On 
physical examination, she exhibited multiple pink 
papules (4-8mm in diameter) in the vulva. Both 
colposcopy and proctoscopy failed to detect any 
lesions. The results of routine laboratory 
investigations were unremarkable. Histological 
examination of biopsy specimens obtained from two 
different lesions revealed the histological features of 
condylomata acuminata, whereas in situ 
hybridization using biotinylated HPV-DNA probes 
showed the occurrence of HPV types 6/11 in the 
nuclei of keratinocytes of the upper epidermal layers. 
Since the patient refused any form of surgical or 
destructive treatment and because of the extent of 
the condylomata, we suggested administration of 
oral isotretinoin. Subsequent to detailed information 
about the possible side effects of this compound, the 
patient gave a written consent and oral treatment 
was initiated with 1mg/kg/day isotretinoin.  
Ten days after onset of treatment a distinct decrease 
in the size of condylomata acuminata could be 
observed. After two weeks of continuous oral 
isotretinoin therapy, the patient developed livid red, 
very tender and painful nodules (1-3cm in diameter) 
on the extensor surface of both tibiae (Figure 1A). 
Histologically the lesions showed features of 
predominantly septal panniculitis, characterized by 
fibrous cords with mixed inflammation consisting of 
neutrophils, lymphocytes, plasma cells, histiocytes, 
and rare multinucleated cells, spilling over to fat 
lobules. The dermis showed also periadnexal and 
perivascular inflammation (Figure 1B). 
In view of the clinical morphology of the lesions and 
the corresponding histological findings, the 
diagnosis of erythema nodosum was established. 
Full blood count revealed a moderate leukocytosis 
and increase of erythrocyte sedimentation rate, 
whereas biochemical parameters and urinalysis were 
unremarkable. Throat swab culture, stool 
examination for bacteria, fungi, and parasites, and 
chest radiograph were negative. Additionally, the 
results of immunological and serological 
investigations were either negative or within normal 
limits. 
Discontinuation of oral isotretinoin administration 
led to a rapid improvement and to a complete 
spontaneous remission of erythema nodosum within 
two weeks. The patient refused an attempt to 
reinitiate oral isotretinoin administration and at her 
request condylomata acuminata were treated with 
electrocauterization. She has presently completed a 
21-month follow-up without any evidence of EN 
relapse. 
 
Figure 1. A) Clinical aspect of erythema nodosum on the right 
tibia of the patient. B) Histology of skin biopsy showing 
predominantly septal panniculitis, with dense inflammatory 
infiltration consisting of neutrophils, lymphocytes, plasma cells, 
and histiocytes. H&E, 25×.  
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Case Discussion 
Through binding to, and activation of retinoic acid 
receptors (RAR), isotretinoin is capable of controlling 
the transcription of specific target genes and of 
exerting a wide range of biological effects including 
regulation of cellular proliferation and 
differentiation, induction of apoptosis, and potent 
immunomodulatory, anti-inflammatory, and anti-
neoplastic action [6]. An inverse relationship has 
been found between the concentrations of retinoids 
and of HPV-DNA within infected epithelial cells, 
indicating that isotretinoin may inhibit the DNA 
replication and assembly of HPV either directly or via 
its ability to affect epithelial differentiation [7]. These 
findings served as the theoretical background for the 
use of oral isotretinoin in the treatment of HPV 
infections with promising results [8, 9]. 
To the best of our knowledge there are only four 
reported cases of EN that occurred during oral 
isotretinoin therapy [10-12]. Interestingly, all of them 
were seen in patients with severe acne. Kelett et al. 
(1985) reported two patients with acne fulminans 
that developed EN during isotretinoin treatment 
[10], whereas a similar case was reported by Tan et al. 
(1997), [11]. In both reports, isotretinoin therapy was 
not discontinued and EN was treated either with 
prednisolone that led to distinct improvement 
within 1 month [10] or dapsone that led to remission 
within 2 weeks [11]. The authors of both reports 
considered the EN to be related to acne fulminans 
and not to isotretinoin. Kellett et al. (1985) supported 
this view by the finding of circulating immune 
complexes in their patients, presumably as part of an 
Arthus reaction triggered by Propionibacterium 
acnes. Krug-Milon also described a patient with 
widespread acne who developed EN during 
isotretinoin treatment. In this case isotretinoin was 
discontinued and EN cleared within two months [12]. 
Since severe forms of acne can trigger EN even in 
patients who are not treated with oral isotretinoin, it 
has been suggested that there is a causative 
relationship between acne and EN [13]. In our 
patient, the possibility that this compound was not 
the causative factor of EN cannot be definitely ruled 
out but seems very unlikely since EN occurred soon 
after initiation of isotretinoin administration and 
rapidly improved after its discontinuation. Moreover, 
a thorough clinical and laboratory investigation 
excluded any other possible triggering factors for EN. 
It is well known that the binding affinity of all-trans-
retinoic acid (atRA) to nuclear retinoid receptors is 
much higher than that of isotretinoin. Thus, steric 
isomerization to atRA is of paramount importance 
for the biologic actions and therapeutic effects of 
isotretinoin (14). Since EN reportedly occurs also in 
patients treated with atRA (15-17), physicians should 
be aware of the fact that EN is side effect that both 
retinoids have in common, regardless of the 
underlying disease for which they are administered.  
 
Conclusion 
To the best of our knowledge, this is the first report 
of EN occurring during oral isotretinoin treatment in 
a patient not suffering from acne. Moreover, it 
strongly indicates that the pathogenetic 
mechanisms of EN are most probably directly related 
to the biological actions of isotretinoin. In 
conclusion, EN should be regarded as a rare side 
effect of oral isotretinoin therapy, regardless of the 
underlying disease. Physicians should be aware of 
this rare adverse reaction.  
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